ASX Announcements
ResMed to Report First Quarter Fiscal 2025 Results
Notification of Results/Reporting Date, Web Casts
- Oct 4, 2024
- 1 page
Notice of Annual General Meeting Additional Materials
Notice of Annual General Meeting
- Oct 4, 2024
- 3 pages
Notice of Annual General Meeting/Proxy Form
Proxy Form, Notice of General Meeting
- Oct 4, 2024
- 104 pages
Yesterday
Why CSL’s earnings outrun CBA, according to this value investor
Investors Mutual’s Daniel Moore says there aren’t too many ASX-listed companies like blood plasma giant CSL that can compound their earnings at such a rate.
- Joanne Tran
This Month
ResMed projects high single-digit revenue growth until 2030
The sleep devices giant expects revenue to grow in the high single-digits for the next five years as it deflects the Ozempic effect.
- Michael Smith
August
New ageing minister held ageing stocks
Anthony Albanese’s addition to the Ministerial Code of Conduct has caused problems for a raft of his ministers.
- Myriam Robin
ASX valuations mask grim reality of a softening economy
Sharemarket investors need to factor in that central banks cut interest rates when economies slow and profit growth splutters.
- Simon Evans
ResMed says sales growth defies weight-loss fears
Chief executive Mick Farrell says he is confident the company has put to bed investor fears that weight-loss drugs will hurt sales of its sleep apnoea products.
- Michael Smith
July
Who are the highest paid ASX 200 CEOs?
New research shows that ASX 100 CEOs earn on average 50 times more than the average Australian adult.
- Hannah Wootton
June
Kean gets top climate job; Cettire dives 44pc; Myer’s huge expansion
Read everything that’s happened in the news so far today.
ResMed sinks as drug trial sparks Ozempic-style sell-off
New results from Eli Lilly’s weight-loss treatment have traders reaching for the sell button, but analysts aren’t so sure.
- Updated
- Joshua Peach
Nine stocks to buy and hold forever
Forget crypto because nothing beats buying and holding a terrific business for the long term to create generational wealth, say fund managers.
- Tom Richardson
May
Fisher & Paykel leaves pandemic behind as respirator demand grows
Earlier this year, Vertium Asset Management’s Jason Teh put the New Zealand-based group on his list of turnaround prospects. Issues at its rival are helping.
- Kylar Loussikian
Loss-making companies are surging on the ASX, baffling analysts
Goldman Sachs is perplexed about the surge in unprofitable stocks, and says there are safer alternatives like retailers Lovisa and Cettire.
- Alex Gluyas
‘Business spends bugger all’: what landmark R&D review aims to fix
Technology industry experts warn a new government review into the R&D system must not cut tax incentives, and must kick-start anaemic business investment.
- Paul Smith, Tess Bennett and Nick Bonyhady
R&D boost needed for Future Made in Australia plan to fly
Australian firms that develop innovative technologies say they are disincentivised to build their products in Australia and are calling for R&D incentive changes.
- Tess Bennett
How Sage Capital is making money from other investors’ panic
Veteran hedge fund manager Sean Fenton has no qualms going against the crowd, buying ResMed after its collapse in 2023.
- Joanne Tran
April
This fundie says CSL is a $500 stock
ECP Asset Management’s Sam Byrnes expects the blood plasma collector’s return on capital to substantially improve and remains bullish on IDP Education even though its share price has tumbled this year.
- Joanne Tran
ASX stocks at risk from Ozempic – and ResMed isn’t one of them
Morgan Stanley brokers say the explosion of interest in the weight loss drugs will be far bigger than first thought. And these major companies could get hit.
- Joshua Peach
The eight stocks most loved by Australia’s best fund managers
Despite the headwinds, CSL is still loved by the top stock pickers. CBA and BHP are also widely held – but not as widely as expected.
- Joshua Peach
March
The stealth compo of Santos CEO Kevin Gallagher
If a CEO’s family gets to fly for free on the corporate private jet, is that worth anything to the CEO?
- Myriam Robin
February
Why analysts love these eight medtech stocks
The sector that straddles healthcare and tech has professionals searching for companies that could be tomorrow’s big winners after Pro Medicus.
- Tom Richardson
Deep Yellow surge puts squeeze on Fidelity’s charity
Even when done altruistically, stock-picking isn’t for the faint-hearted.
- Myriam Robin